HSICHealthcare · Medical DistributionThe 16 Wall Street analysts covering Henry Schein, Inc. hold a median 12-month price target of $100 — +15.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 15 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Henry Schein, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Accruals (50): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HSIC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +15.8% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | BTIG | Maintains | Buy | $100 → $110 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | — |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $86 → $100 |
| 5 Aug 2026 | BTIG | Reiterates | Buy | — |
| 5 Aug 2026 | BTIG | Reiterates | Buy | $100 |
| 5 Aug 2026 | Citigroup | Maintains | Buy | — |
| 5 Aug 2026 | Citigroup | Maintains | Buy | $100 → $112 |
| 5 Aug 2026 | UBS | Maintains | Neutral | $89 → $94 |
| 5 Aug 2026 | UBS | Maintains | Neutral | — |
| 29 July 2026 | Piper Sandler | Maintains | Overweight | $91 → $95 |
| 29 July 2026 | Piper Sandler | Maintains | Overweight | — |
| 28 July 2026 | UBS | Maintains | Neutral | $85 → $89 |
| 28 July 2026 | UBS | Maintains | Neutral | — |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 11 June 2026 | BTIG | Upgrade | Buy | — |
| 6 May 2026 | Mizuho | Maintains | Neutral | — |
| 6 May 2026 | UBS | Maintains | Neutral | — |
| 24 Apr 2026 | Morgan Stanley | Maintains | Underweight | — |
| 16 Apr 2026 | BTIG | Initiates | Neutral | — |
| 15 Apr 2026 | Citigroup | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HSIC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, Henry Schein, Inc. returned +39.3% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 75% of US stocks
Cheaper than 30% of US stocks
Cheaper than 25% of US stocks
Higher than 43% of US stocks
Higher than 47% of US stocks
Higher than 37% of US stocks
Higher than 56% of US stocks
Higher than 55% of US stocks
Higher than 61% of US stocks
Higher than 73% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Henry Schein, Inc. has a market value of $9.9B and an enterprise value of $14.9B.
Revenue in the twelve months to 30 June 2026: $13.6B. The latest quarter grew 6.7% year on year.
Net income over the same four quarters: $426.0M, a 3.1% net margin.
Diluted earnings per share, trailing twelve months: $3.43.
Free cash flow in the twelve months to 30 June 2026: $513.0M, after $56.0M of capital spending.
Henry Schein, Inc. spent $728.0M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 24.8×; forward P/E: 14.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Henry Schein, Inc. employs 25,000 people — $544K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| HSICHenry Schein, Inc. | $9.9B | 83 |
| CAHCardinal Health, Inc. | $58.7B | 96 |
| CORCencora, Inc. | $65.2B | 74 |
| MCKMcKesson Corp. | $116.9B | 90 |
| OSCROscar Health, Inc.* | $10.0B | 89 |
| GKOSGlaukos Corp.* | $9.8B | 87 |
| KRYSKrystal Biotech, Inc.* | $9.8B | 76 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Henry Schein, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Henry Schein as a top-ranked value stock and describes its Style Scores as a way for investors to find stocks aligned with their investing style.
Why it matters — HSIC watchers may note the article’s value-stock ranking and its reference to Zacks’ style-based stock-screening tool.
Henry Schein named former ITT CFO Emmanuel Caprais as its senior vice president and CFO, effective November 4, 2026. He will join the Henry Schein Leadership Team and report to CEO Frederick M. Lowery.
Why it matters — The leadership transition identifies who will oversee Henry Schein’s finance function and when the appointment takes effect.
Zacks Investment Research compares Henry Schein and Merit Medical as potential value stocks in the Medical - Dental Supplies sector, asking which currently presents the better value opportunity.
Why it matters — The comparison puts HSIC’s relative value among sector stocks in focus for investors following the company.
The excerpt describes Zacks’ focus on its earnings-estimate and estimate-revision-based Zacks Rank, while also monitoring value, growth, and momentum trends. It does not provide a specific assessment of Henry Schein.
Why it matters — HSIC watchers get context on the investment factors Zacks says it considers, but the excerpt gives no company-specific conclusion.
Henry Schein Cares, Henry Schein, Inc.'s global corporate citizenship program, is marking its 25th anniversary. The program unites Team Schein Members, customers, supplier partners, healthcare professionals, and nonprofit organizations to improve global health, and now operates through five interconnected pillars including Catalyzing Healthcare Access and Advancing Policies.
Why it matters — The milestone highlights Henry Schein's longstanding corporate citizenship efforts and its collaborative engagement across its customer, supplier, and community networks, reflecting positively on the company's reputation and stakeholder relationships.
The 16 Wall Street analysts covering Henry Schein, Inc. have a median 12-month price target of $100, with estimates ranging from $64 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Henry Schein, Inc., 8 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Henry Schein, Inc. 83 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Oct 2026, Henry Schein, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +15.8% from the last close, and Ticker Nerd's factor model ranks Henry Schein, Inc. 83 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Henry Schein, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HSIC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $64 to $110 over the next 12 months.
Henry Schein, Inc. returned +39.3% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Henry Schein, Inc. is a health care solutions company that serves office-based dental, medical, and veterinary professionals.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "Henry Schein (HSIC) is a Top-Ranked Value Stock: Should You Buy?". Zacks Investment Research highlights Henry Schein as a top-ranked value stock and describes its Style Scores as a way for investors to find stocks aligned with their investing style.
Henry Schein, Inc. is a health care solutions company that serves office-based dental, medical, and veterinary professionals. Henry Schein provides a broad range of products and services through its core businesses in healthcare distribution, specialty products, and technology-enabled value-added services. Its offerings include consumable supplies, dental equipment, practice-management software, logistics support, and related clinical solutions that help practices manage daily operations more efficiently. The company also supports dental laboratories, government and institutional health care clinics, and other alternate care sites with products and services tailored to professional workflows. With a strong presence in dental and medical markets, Henry Schein plays an important role in the supply chain for outpatient health care providers and practice support services.
CEO Mr. Frederick M. Lowery · 25,000 employees · United States · https://www.henryschein.com
